Racemose haemangiomatosis of the retina is a sporadic, mostly unilateral, congenital arteriovenous malformation (AVM), comprising abnormal junctions between arteries and veins that omit capillaries. Typically, vascular malformations are asymptomatic and incidentally discovered. Advanced changes may be related to the presence of subretinal fluid and exudates, even though these lesions are classified as benign. Many complications can lead to severe or permanent visual impairment. Direct methods of treatment of primary retinal vascular anomalies have not been developed yet. The aim of this case report is to present the anti-VEGF therapy in the treatment macular oedema secondary to racemose haemangioma.
introduCtion
The vascular tumours of the retina comprise a diverse group of congenital and acquired lesions, that include capillary haemangioma, cavernous haemangioma, racemose haemangiomatosis, and retinal vasoproliferative tumour [1, 2] .
Racemose haemangiomatosis of the retina is a sporadic, mostly unilateral, congenital arteriovenous malformation (AVM), comprising abnormal junctions between arteries and veins that omit capillaries. If similar vascular malformations coexist in the same side of the brain, that relation is considered as a Wyburn-Mason syndrome (also known as Bonnet-Dechaumme-Blanc syndrome). Lesions may also be located in the skin, bones, muscles, kidneys, and in gastrointestinal tract [3, 4] . Typical clinical manifestation reveals characteristic dilated and tortuous retinal vessels that can extend from the optic disc to the retinal periphery [5] . Depending upon the severity of the vascular malformation, they are classified into three distinct groups: Group I AVMs possesses abnormal capillary plexus between the large vessels; Group II shows a lack of capillary vessels; and Group III includes the most extensive AVMs, with dilated and tortuous vessels [6] .
Fluorescein angiography (FA) demonstrates anomalous arteriovenous communications and the hyperfluorescense without leakage (Fig. 1) . Typically, vascular malformations are asymptomatic and incidentally discovered. Bigger changes may be related with the presence of subretinal fluid and exudates. In the diagnosis and monitoring of the disease, optical coherence tomography (OCT) is found to be useful [7] .
Anti-VEGF therapy is an option in managing complications of retinal arteriovenous anomalies [8] .
Case report
A 41-year-old female patient reported to the Department of Vitreoretinal Surgery of the Medical a B
University in Lublin complaining about deterioration of vision in her right eye. In a clinical examination, we found that the best corrected visual acuity (BCVA) in the right eye was 0.3, and in the left eye -1.0. Examination of the anterior segment of the both eyes with a slit lamp showed no abnormalities. Fundus examination of the right eye revealed the presence retinal racemose haemangioma ( Fig. 2) and secondary macular oedema. OCT of the right eye showed cystoid macular oedema (CMO) (Fig. 3) . The patient was qualified to intravitreal injection of anti-VEGF (Vascular Endothelial Growth Factor) -bevacizumab to her right eye. One month (Fig. 4) .
disCussion
Retinal vascular malformations are benign, usually asymptomatic, and discovered incidentally during ophthalmologic examination. However, in many cases, they can cause significant deterioration of vision by various mechanisms. Blood vessels tortuosity can lead to the closure of their barrel [9, 10], retinal ischaemia [11] , and neovascular glaucoma [12] . It can also lead to macular haemorrhage, serous pigment epithelium detachment, and cystoid macular oedema [13, 14] .
Direct methods of treatment of primary retinal vascular anomalies have not been developed yet. Only the above-mentioned complications are covered by the treatment. In 2006 Soliman et al. described a case of treatment of a patient with bilateral racemose haemangioma by photocoagulation of the vascular leakage points [15] . However, considering the age of patients, the incidence of CMO near the fovea, and the risk of subretinal choroidal neovascularization, which entails photocoagulation, treatment with anti-VEGF preparations is much safer [16] .
Currently, the literature describes one case of treatment CMO in the course of retinal racemose haemangioma by intravitreal injection of bevacizumab [16] . The exact mechanism of action in this case is unknown; however, by decreasing the vascular permeability and increasing the number of tight junctions between proteins a significant reduction of subretinal fluid was obtained [16] .
In our case intravitreal injection of bevacizumab resulted in complete regression of the CMO in the right eye, which was associated with the return of full visual acuity. The therapy applied in this case was a safe and effective method against cystoid macular oedema in the course of retinal racemose haemangioma. At the time of writing, after six months of observation, the macular oedema has not recurred. However, patients with racemose haemangiomatosis of the retina should be carefully monitored because such treatment is directed towards secondary retinal changes, not to the primary disease. 
